A few ER+/HER2− breast cancer cells overexpressing KAT6B showed inhibitory activity against the KAT6‐specific inhibitor, but no significant correlation was observed between KAT6B expression and drug sensitivity. Here, ESR1 is linked to breast carcinoma.